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A B S T R A C T 
Background: Cisplatin has a potency of causing nephrotoxicity. Serum BUN and 
creatinine levels have been well-known for detecting kidney dysfunction; while KIM-1 
and NGAL urine levels are relatively new measurements. The study was aimed to 
evaluate urinary KIM-1 and NGAL level to detect kidney dysfunction in patients with 
advanced stage NPC who received cisplatin-based chemotherapy.   
 
Methods: The study was a cohort-prospective study with 3 subject groups, i.e. patients 
who had never received and who had received 75-100 mg/m2 cisplatin-based 
chemotherapy as well as those who had never received 40 mg/m2 cisplatin-based 
chemotherapy. The levels of urinary KIM-1, NGAL and serum level of BUN and 
creatinine were measured before and after receiving cisplatin. Statistical analyses were 
ANOVA, Pearson, Spearman, Kolmogorov-Smirnov test and SPSS version 22.0. 
 
Result: There was a significant difference of delta BUN level (p=0.0001) and delta 
urinary NGAL level (p = 0.025) before and after treatment in all three groups; while 
delta KIM-1 level showed no significant difference in all three groups (p=0.275). 
Cisplatin may cause accumulated nephrotoxicity, which has dose-dependent manner. 
 
Conclusion: Measuring urinary NGAL level can detect an early stage of kidney 
dysfunction; however, it still cannot replace the role of BUN. Measurement of urinary 
KIM-1 level cannot detect kidney dysfunction. 
 
  
INTRODUCTION 
 
Cisplatin is the main treatment for nasopharyngeal 
carcinoma. The cancer is rare worldwide, but it has an 
essential clinical importance as it is commonly 
misdiagnosed and has a remarkable geographical and 
racial distribution. Nasopharyngeal carcinoma (NPC) is 
widely found in Asia, particularly in China and South 
East Asia, including Indonesia. The global incidence of 
NPC is 1 : 100,000 (1,2). In Indonesia, the incidence may 
reach 6.2 per 100,000 citizens annually, or it is assumed 
that there are 13,000 new cases per year (3). The 
incidence may also depend on racial and geographical 
distribution as different areas may affect different 
histological and etiological appearance (4). The cancer 
may bring a relatively huge economic burden to health 
care cost of a country since the cancer is mostly present 
in male patients at their productive age (1).  
Cisplatin has been known as a highly effective 
chemotherapeutic drug for NPC (6). However, it has also 
been described as a drug with quite significant side 
effects and toxicities. One of the most common 
toxicities of cisplatin is nephrotoxicity which may cause 
kidney dysfunction (7). Kidney dysfunction due to 
cisplatin nephrotoxicity is usually started with the 
development of apoptosis of the proximal tubule cells 
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that continually develops into acute kidney injury in the 
form of acute necrosis. It is assumed that long-term 
cisplatin treatment may cause the development of cystic 
tubules. Moreover, Yao et al. (2) have also assumed that 
the degree of severity of the necrosis is dose-dependent 
and time-dependent. Yao et al. (2) have also suggested 
that about 20% of patients who had high-dose cisplatin 
treatment are likely to have severe kidney dysfunction. 
However, no definite study has clearly elaborated the 
effect on nephrotoxicity due to low-dose cisplatin 
treatment. Other studies have also demonstrated that 
nephrotoxicity caused by cisplatin is extremely dose-
dependent (2,3). Acute kidney failure, either with or 
without oliguria, may develop in 2-6 days after the 
patient has been given high-dose cisplatin treatment, 
while chronic kidney failure may occur due to a set of 
intravenous cisplatin of at least 20 mg/m2/day for 5 
days which is given once in every 3 weeks. The chronic 
kidney dysfunction may last for over 2 years (3).  
Kidney dysfunction caused by the anticancer 
treatment should be detected early. Usually, kidney 
damage can be detected by measuring the serum levels 
of blood urea nitrogen (BUN) and creatinine, which are 
easily calculated and providing fast results (4). Yao et al. 
(2) have suggested that the concentration of cisplatin in 
proximal tubule cells may reach 5 folds of the serum 
concentration. Therefore, it is expected that 
measurement using urinary levels of biomarker can 
provide a more accurate evaluation on the kidney 
function than using the serum level of creatinine and 
urea. Some biomarkers may provide a quite promising 
result to detect kidney dysfunction including the 
neutrophil gelatinase-associated lipocalin (NGAL) and 
kidney injury molecule-1 (KIM-1). It is expected that 
NGAL can be used as a biomarker for detecting the early 
stage of damage in cortical tubules of the kidney, while 
KIM-1 may exhibit a relatively good sensitivity to detect 
proximal tubular damage of the kidney, either the 
damage is acute, sub-chronic or chronic (10).  
Nevertheless, studies on biomarkers using urinary 
levels of KIM-1 and NGAL to predict the presence of 
kidney dysfunction in patients with nasopharyngeal 
patients treated with cisplatin had never been 
conducted in Indonesia. Therefore, our study was aimed 
to evaluate the urinary KIM-1 and NGAL levels for 
detecting kidney dysfunction in patients with NPC who 
were treated with cisplatin-based chemotherapy. 
 
MATERIAL AND METHOD 
 
This study is a cohort prospective study conducted in 
patients with NPC who had been treated with cisplatin-
based chemotherapy. The study was conducted in Cipto 
Mangunkusumo Hospital, Jakarta, Indonesia and data 
collection was performed after an ethical clearance had 
been issued (No. 987/UN2.F1/ETIK/2016) by the Ethics 
Committee at Faculty of Medicine, University of 
Indonesia and (No. LB.02.01/X2/10942016) by Cipto 
Mangunkusumo Hospital. Blood and urinary sampling 
were performed on patients with NPC who were 
hospitalized at the A ward in the Department of Internal 
Medicine, Division of Hematology and Medical Oncology 
of Cipto Mangunkusumo Hospital. The study was 
conducted for three months starting from December 
2016 to February 2017. Data management was 
performed at the Laboratory of Pharmacology and 24-
hour Clinical Pathology Laboratory at Cipto 
Mangunkusumo Hospital. The technique used for 
sampling was consecutive sampling.  
Patients who became our study subjects were 
patients with NPC who had cisplatin-based 
chemotherapy at the dose of 75-100 mg/m2 and 40 
mg/m2. The subjects were categorized into 3 groups: (1) 
NPC patients who had never been exposed to cisplatin-
based chemotherapy of 75-100 mg/m2; (2) NPC patients 
who had been treated with cisplatin-based 
chemotherapy at least a cycle of 75-100 mg/m2 dose; 
(3) NPC patients who had never been exposed to 
cisplatin-based chemotherapy of 40 mg/m2 dose.   
Measurements of KIM-1 and NGAL urinary levels, and 
BUN and creatinine serum levels were performed on 
day 0 and day 5 (before and after cisplatin treatment) in 
NPC patients who received cisplatin-based 
chemotherapy at 75-100 mg/m2 dose (group 1 and 2) 
and the measurements were done on day 0 for those 
who received cisplatin-based chemotherapy at 40 
mg/m2 dose (group 3). (Figure 1) 
The inclusion criteria were: (1) Patients with NPC aged 
18-59 years old who had never been exposed to 
cisplatin-based chemotherapy of adjusted dose to their 
clinical condition of 75-100 mg/m2; (2) Patients with 
NPC aged 18-59 years old who had received cisplatin-
based chemotherapy of adjusted dose to their clinical 
condition of 75-100 mg/m2 for at least one cycle; (3) 
Patients with NPC aged 18-59 years old who had never 
been exposed to cisplatin-based chemotherapy of 40 
mg/m2.5  The exclusion criteria were patients with 
severe disease (end-stage chronic kidney failure, heart 
failure) so that they could not participate and complete 
the study and patients who were unwilling to 
participate the study.  Eligible patients were recruited as 
study subjects and underwent measurement of urinary 
KIM-1 and NGAL as well as serum BUN and creatinine 
levels. The measurement of urinary KIM-1 and NGAL 
levels was performed at the Laboratory of 
Pharmacology, Faculty of Medicine, University of 
Indonesia. Details of the procedure are provided below, 
while the measurement of serum BUN and creatinine 
levels was carried out in the 24-hour Clinical Pathology 
Laboratory at Cipto Mangunkusumo Hospital, Jakarta 
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Figure 1. Algorithm of the study flow 
 
Measurement of KIM-1 and NGAL in urine 
 
The measurement of urinary KIM-1 and NGAL level 
was carried out using an ELISA kit (Human KIM-1 and 
Human NGAL, Elabscience, catalogue number: E-EL-
H0186 and E-EL-H0096) with Sandwich-ELISA method. 
Urine samples were collected from study subjects to 
measure urinary KIM-1 and NGAL level. We collected 
first voided morning urine sample in sterile containers 
and stored at -20
o
C. All taps of samples were tightened 
to prevent evaporation and microbial contamination. In 
the laboratory, urine samples were centrifuged for 20 
minutes at 1000g at 2-8
o
C and subsequently the 
supernatants were analysed immediately. Before 
performing the analysis, standard reagent was prepared 
and brought to room temperature (18-25
o
C) within 15 
minutes before use.     
Urine samples and standard reagent are added to the 
appropriate micro ELISA plate wells and combined with 
specific antibody. Then a biotinylated detection 
antibody specific for KIM-1/NGAL and Avidin-
Horseradish Peroxidase (HRP) conjugate is added to 
each micro plate well and incubated. Free components 
are washed away using wash buffer. The substrate 
solution was added to each well. The well containing 
KIM-1/NGAL biotinylated detection antibody and avidin-
HRP conjugate appeared in blue colour. The enzyme-
substrate reaction was terminated by addition of a 
sulphuric acid solution and the color turned yellow. The 
optical density (OD) was measured 
spectrophotometrically at the wavelength of 450 nm + 2 
nm. The OD value was proportional to the concentration 
of KIM-1/ NGAL.  The concentrations of KIM-1/ NGAL in 
the samples were measured by comparing the OD of the 
samples to the standard curve.  
Univariate and bivariate analyses were used in our 
study. Univariate analysis was performed to identify the 
correlation between urinary KIM-1 and NGAL levels and 
BUN and creatinine serum levels in each group using 
scatter plot diagram. Bivariate analysis was used to 
measure delta difference of KIM-1 and NGAL urinary 
level and delta difference of BUN and creatinine serum 
levels to compare kidney function before and after 
having cisplatin-based chemotherapy in each group. 
ANOVA test was used in bivariate analysis when the 
data distribution was normal, while Kruskal Wallis test 
was used when the data distribution was abnormal. The 
p value of ≤ 0.05 was determined as the acceptable 
significance level. Data was presented in the form of 
text, tabels, and box plots using Graphpad Prism Version 
5.01. Both univariate and bivariate analyses were 
performed using SPSS version 22.0. Afterwards, multi 
comparison analysis was performed using post-hoc 
Tukey test.   
 
RESULTS 
 
Total subjects who participated in the study were 46 
patients. The number of subjects who had received 
cisplatin-based chemotherapy of 75-100 mg/m2 dose 
was 31 subjects that consisted of 13 subjects of NPC 
patients in the group that had never been exposed to 
prior chemotherapy and 18 NPC patients who had 
received chemotherapy of at least 1 cycle. Our study 
also included data of 15 subjects who had cisplatin-
based chemotherapy with a dose of 40 mg/m2.  All 
subjects had completed the study and no subject was 
lost to follow up. 
Data on subject characteristics of all groups was 
comparable as can be seen in table 1. 
 
Evaluation of kidney dysfunction based on the 
correlation between KIM-1 and NGAL urinary levels 
and BUN and creatinine serum levels  
 
 In general, our study showed that the NGAL and KIM-
1 urinary level did not have any correlation and had a 
weak correlation with BUN and creatinine serum levels 
in almost all groups. However, a strong correlation 
between creatinine serum level and NGAL urinary level 
was found in one group, i.e. the group that had never 
received chemotherapy of 75 mg-100 mg/m2. (Figure 2 
and Figure 3)  
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Table 1. Subject Characteristics 
 
Variables 
Group 1 
n =13 
Group 2 
n=18 
Group 3 
n=15 
Mean ± SD Number % Mean ± SD Number  % Mean ± SD Number % 
Characteristics Male 
 
12(92.31) 
 
14(77.78) 
 
10(66.67) 
 
Female 
 
1 (7.69) 
 
4 (22.28) 
 
5 (33.33) 
 
Age (years) 42.62 ± 12.29 
 
49.56 ± 13.82 
 
42.67 ± 12.23 
 
 
Weight(kg) 53.38 ± 12.06 
 
54.47 ± 12.94 
 
52.50 ± 7.91 
 
 
Height (cm) 158.15 ± 16.86 
 
164.22 ± 7.89 
 
162.07 ± 8.26 
 
 
Body surface  (mm2) 1.47 ± 0.24 
 
1.56± 0.20 
 
1.55 ± 0.13 
 Ethnics Bataknese 
 
1 (7.69) 
 
1 (5.56) 
 
1(6.67) 
 
Batamian 
 
1 (7.69) 
    
 
Bengkulunese 
   
1 (5.56) 
  
 
Javanese 
 
10 76.92) 
 
12(66.67) 
 
11(73.33) 
 
Chinese descendants 
   
1 (5.56) 
 
2 (13.33) 
 
Padangnese 
 
1 (7.69) 
 
3(16.67) 
 
1 (6.67) 
 
Bogorian 
      
 
Floresian 
      
 
Jakartan 
      Occupation Civil servants/ 
Pension 
 
1(7.69) 
 
1 (5.56) 
 
3 (20) 
 
Private sector 
employee 
 
7(53.85) 
 
6 (33.33) 
 
5 (33.33) 
 
Housewives 
 
1(7.69) 
 
3 (16.67) 
 
3 (20) 
 
Entrepreneurs 
 
2(15.38) 
 
6  (33.33) 
 
3 (20) 
Students 2(15.38) 2 (11.11) 1 (6.67) 
 
 
 
 
 
 
 
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Correlation between delta difference of NGAL urinary levels and delta difference of BUN and creatinine serum 
levels. (A) Correlation between delta difference of NGAL urinary levels and delta difference of creatinine serum levels in 
three groups.  (B) Correlation between delta difference of NGAL urinary levels and delta difference of BUN serum levels in 
three groups: Group 1: NPC patients who had never been exposed to cisplatin-based chemotherapy of 75-100 mg/m
2
; 
Group 2:  NPC patients who had been treated with cisplatin-based chemotherapy at least a cycle of 75-100 mg/m
2 
dose; 
Group 3: NPC patients who had never been exposed to cisplatin-based chemotherapy of 40 mg/m
2 
dose.  
 
A1. Group 1 
 
B1. Group 1 
A2. Group 2 B2. Group 2 
A3. Group 3 B3. Group 3 
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Evaluation of kidney dysfunction based on delta 
difference of BUN and creatinine serum level and KIM-
1 and NGAL urinary level  
 
 The delta difference of BUN and creatinine serum 
levels as well as KIM-1 and NGAL urinary levels between 
before and after chemotherapy treatment can be seen 
in figure 4. Our study showed that the delta difference 
of NGAL urinary level was normally distributed and 
therefore, an ANOVA test was performed. In contrast, 
the delta difference of KIM-1 urinary level, creatinine 
and BUN serum levels were not normally distributed, in 
which the Kruskal Wallis took place.  
 Data of our study demonstrated that there was a 
significant delta difference of NGAL urinary level 
between before and after treatment in all of the three 
groups (p=0.025). Moreover, the ANOVA test had also 
demonstrated that there was a significant mean 
difference in two groups, i.e. in the group that had 
never received chemotherapy of 40 mg/m2 dose 
(p=0.02) and in the group of those who had received 
chemotherapy at 75-100 mg/m2 (p=0.02). On the 
contrary, the delta difference of KIM-1 urinary level in 
three groups was not significant (p=0.275) and the delta 
difference of creatinine serum level was also not 
significant between before and after treatment in three 
groups (p=0.140). However, the delta difference of BUN 
serum level in our study was significant between before 
and after treatment in three groups (p=0.0001). 
Figure 3. Correlation between delta difference of KIM-1 urinary levels and delta difference of creatinine and BUN serum 
levels. (A) Correlation between delta difference of KIM-1 urinary levels and delta difference creatinine serum levels in three 
groups; (B) Correlation between KIM-1 urinary levels and delta difference BUN serum levels in three groups: Group 1: NPC 
patients who had never been exposed to cisplatin-based chemotherapy of 75-100 mg/m2; Group 2:  NPC patients who had 
been treated with cisplatin-based chemotherapy at least a cycle of 75-100 mg/m2 dose; Group 3: NPC patients who had 
never been exposed to cisplatin-based chemotherapy of 40 mg/m2 dose. 
A1. Group 1 
 
B1. Group 1 
 
A2. Group 2 
 
B2. Group 2 
 
A3. Group 3 
 
B3. Group 3 
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Figure 4. Delta difference of KIM-1 urinary levels, NGAL urinary levels, BUN and creatinine serum levels between before and after 
chemotherapy in three groups. (A) Delta of NGAL urinary levels;  (B) Delta of KIM-1 urinary levels;  (C) Delta of creatinine serum levels;  
(D) Delta of BUN serum levels
 
DISCUSSION 
 
Chemotherapy is the main treatment for advanced 
stage carcinoma. However, the use of Chemotherapy 
often becomes limited due to its side effects. Cisplatin is 
the main chemotherapy for advanced stage NPC. It may 
cause kidney dysfunction or has a nephrotoxic 
characteristic. However, data about the effect of 
cisplatin as NPC chemotherapy is still very limited, 
particularly the data about kidney dysfunction that may 
develop.  
 
 
Kidney dysfunction caused by the anticancer 
treatment should be detected early. In general, kidney 
damage can be detected by measuring the serum levels 
of creatinine and blood urea nitrogen (BUN). Other than 
BUN and creatinine serum levels, some biomarkers 
were assumed to be sensitive and reliable to establish 
the diagnosis of kidney dysfunction including the urinary 
levels of KIM-1 (kidney injury molecule-1) and NGAL 
(neutrophil gelatinase-associated lipocalin). Measuring 
the levels of those biomarkers in the urine has also been 
assumed that the biomarker can predict earlier acute 
kidney damage.  
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The results of the study showed that cisplatin can 
cause kidney dysfunction as shown by a significant delta 
difference of BUN serum level between before and after 
treatment in three groups (p=0.0001).  
Our study also showed that there was a higher delta 
difference of BUN serum level in subjects receiving 
cisplatin-based chemotherapy of 75-100 mg/m2 
compared to those receiving at 40 mg/m2 dose. It 
indicates that there is a kidney dysfunction due to 
cisplatin, which is dose dependent and there is an 
accumulation effect of cisplatin dose on nephrotoxicity. 
The dose dependent effect of cisplatin in our study is 
obvious in subjects who had never received cisplatin, 
but then subsequently received cisplatin at 40 mg/m2. 
Those subjects had a lower delta difference of BUN 
serum level compared to the subjects receiving 75-100 
mg/m2 cisplatin as they received far less exposure of 
cisplatin.  
Similar results have also been shown by other studies. 
Espeli et al. (5) have reported that there is a significant 
reduction of kidney function in patients who had been 
given cisplatin at the dose of 40 mg/m2  compared to 
patients who had been given 100mg/m2 (p=0.04). Rades 
et al. (6) have demonstrated that there is a significant 
reduced kidney function in patients with 20 mg/m2 
cisplatin compared to those receiving 100mg/m2 
cisplatin (1% vs. 8% patients with third degree of kidney 
dysfunction). Moreover, the accumulation effect of 
cisplatin in our study has also been showed by a higher 
delta difference of BUN serum level in subjects who had 
received several cycles of 75 -100 mg/m2 cisplatin than 
those who had never received chemotherapy. Cisplatin 
can be accumulated in the kidney, increases membrane 
fragility of tubular cells, and causing acute tubular 
necrosis and tubular dilatation that can be manifested 
as increased BUN and creatinine serum levels. 
Arunkumar et al. (7) in their study has demonstrated the 
nephrotoxicity of cisplatin in cervical cancer, esophageal 
cancer, head and neck cancer as well as showing that 
cisplatin can be accumulated in the kidney and the 
nephrotoxicity occurs in dose dependent manner. 
In daily clinical practice, kidney dysfunction is usually 
detected by measuring BUN and creatinine serum level. 
In our study, there was a significant delta difference of 
BUN serum level between before and after treatment in 
three groups (p=0.000), while the creatinine serum level 
was not significantly different (p=0.140). It suggests that 
cisplatin can cause kidney dysfunction, although the 
damage is still very mild. Nguyen (8) in his literature 
review said that the creatinine serum level usually does 
not change until there is about 50% of kidney 
dysfunction. In acute kidney dysfunction, the glomerular 
filtration is reduced and therefore creatinine serum 
level is not accurate enough to illustrate the status of 
kidney function until the balance takes place, in which 
the process may need a relatively long period of time. 
Our study result is different from those in the study 
conducted by Hoek et al. (9) showing that the 3rd 
degree nephrotoxicity (creatinine serum level of >3x) 
occurred more frequently in subjects who had received 
prior cisplatin chemotherapy compared to those who 
never received any chemotherapy (0% vs. 8%). The 
difference may be due to factors affecting creatinine 
serum level, which in our study were not controlled or 
measured. Some of those factors are age, sex, muscle 
mass, muscle metabolism and hydration status (8). 
Other researchers have also mentioned that hydration 
status, diuresis and electrolyte status of the patients 
may probably affect nephrotoxicity caused by cisplatin-
based chemotherapy. Rades et al. (6) have reported that 
hydration and dieresis may protect the nephron of the 
group given cisplatin-based chemotherapy at the dose 
of 100 mg/m2 and Arunkumar et al. (7) have shown that 
cisplatin may induce nephrotoxicity through the 
mechanism of electrolyte reabsorption disorder in the 
kidney tubular cells.  
Regarding the relatively new biomarkers for kidney 
dysfunction, our study showed that there was a 
significant delta difference of NGAL urinary levels 
between before and after treatment in three groups 
(p=0.025). There was also a significant difference in a 
pair of groups, i.e. the group that had never received 
chemotherapy of 40 mg/m2 (p=0.02) and in the group 
that had been treated with 75-100 mg/m2 
chemotherapy (p=0.02). Therefore, our study has 
demonstrated that measuring NGAL urinary level may 
detect kidney dysfunction. Some studies have also 
supported the results of our study. According to Shirali 
(10), the NGAL urinary or serum level will increase in 
those with acute kidney failure due to nephrotoxin such 
as cisplatin, aminoglycosides and other nephrotoxic 
drugs. Mishra et al. (11) have also demonstrated 
increased gene expression of NGAL in renal ischemia 
and the urinary level in mice can be rapidly increased 
within only 3 hours after cisplatin administration. It is 
also supported by Van Meer L et al. (4) who have 
suggested that the NGAL urinary level can be used as a 
biomarker for detecting early stage acute damage in 
cortical tubules of the kidney. The effect of 
accumulation and dose-dependent characteristic can be 
described by an obvious mean of difference in a pair of 
groups, i.e. those who had never received 40 mg/m2  
chemotherapy and those who had received 75-100 
mg/m2 chemotherapy. Therefore, the measurement of 
NGAL urinary level still cannot replace the measurement 
of BUN serum level to detect kidney dysfunction in 
patients with advanced stage NPC who received 
cisplatin chemotherapy.  
Furthermore, our study showed that the delta 
difference of KIM-1 urinary level in all three groups was 
not significantly different (p=0.275). Therefore, the KIM-
1 urinary level still cannot be used as a biomarker for 
detecting kidney dysfunction due to cisplatin 
chemotherapy in patients with advanced stage NPC. 
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Results of our study were in contrary to some 
experimental studies, which suggest that KIM-1 urinary 
level is a more sensitive biomarker than the 
conventional biomarkers of BUN and creatinine serum 
level in detecting kidney dysfunction caused by 
nephrotoxin in mice. Vaidya et al. (12) have measured 
KIM-1 urinary level in mice. Their study has shown that 
KIM-1 is sensitive and the level is increased significantly 
in kidney injury. Tonumura et al. (11) have also shown 
that KIM-1 urinary level is increased significantly in mice 
within 24 hours following cisplatin administration, which 
also indicates that KIM-1 can detect the injury in kidney 
proximal tubule following cisplatin administration. 
However, data in human is still limited and KIM-1 
reagent is not available for commercial purpose. 
Therefore, the validity of KIM-1 as biomarker for 
detecting kidney injury in human is still vague (13). 
In general, our study has shown that NGAL and KIM-1 
urinary levels have weak correlation with BUN and 
creatinine serum levels in almost all groups. It indicates 
that KIM-1 and NGAL urinary level still cannot be used 
to replace the role of BUN and creatinine serum levels in 
detecting mild kidney dysfunction caused by cisplatin-
based chemotherapy in patients with advanced stage 
NPC. No previous study available that shows the 
correlation of BUN and creatinine serum levels with the 
KIM-1 and NGAL urinary levels. However, some 
researchers have different opinions about it.  
Han WK et al. (14) suggest that measurement of KIM-
1 urinary level may serve as a diagnostic biomarker for 
acute kidney dysfunction. Their study has demonstrated 
increased KIM-1 urinary level can be detected within 12 
hours after the development of kidney ischemia in 
patients with acute dysfunction caused by various other 
clinical etiologies. While Liangos et al. (15) showed that 
increased KIM-1 urinary level in 201 patients with acute 
kidney failure has significantly association with poor 
prognosis including increased mortality rate or 
increased needs in dialysis. Moreover, Chaturvedi et al. 
(13) in their study demonstrate that although KIM-1 
examination may be used routinely in clinical studies, 
but its application in daily practice should be studied 
further and validated.  
Furthermore, our study has also shown a strong 
correlation between creatinine serum level and NGAL 
urinary level, which was found only in a group, i.e. the 
group that never had chemotherapy of 75 mg-100 
mg/m2. The result is consistent with the result of a 
study conducted by Nguyen et al. (8), which has 
demonstrated that NGAL urinary level actually has a 
relatively good correlation with increased creatinine 
serum level. Therefore, NGAL may serve as a relatively 
sensitive biomarker for detecting early kidney injury.  
There are some limitations in our study since the 
study was only performed at a single hospital with a 
small population size. Further studies with larger 
population and greater collaboration with other 
hospitals are necessary to provide greater impacts on 
daily clinical practice. 
 
CONCLUSION 
 
Our study shows that cisplatin can cause kidney 
dysfunction or has nephrotoxic characteristic. The 
measurement of NGAL urinary level can be used for 
detecting kidney dysfunction. However, it cannot 
replace the role of BUN serum level measurement to 
detect kidney dysfunction in patients with advanced 
stage NPC who received cisplatin chemotherapy. On the 
contrary, the measurement of KIM-1 urinary level still 
has not shown its role as a biomarker for detecting 
kidney dysfunction due to cisplatin chemotherapy in 
patients with advanced stage NPC.  
Kidney dysfunction caused by cisplatin can 
accumulate in the kidney and the nephrotoxicity is in 
dose dependent manner. The effect of dose dependent 
shown by cisplatin in our study is apparent as the 
subject who had never received cisplatin and then got 
cisplatin at 40 mg/m2 had a lower delta difference BUN 
serum level than those who had been exposed by 
cisplatin at the dose of 75-100 mg/m2. It may occur 
because the subjects had less dose of cisplatin.  
Further studies are necessary to evaluate the role of 
measuring KIM-1 and NGAL urinary levels as biomarker 
for kidney dysfunction in NPC patients who received 
cisplatin-based chemotherapy. The studies should be 
conducted with larger sample size and better method of 
study. 
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